38 related articles for article (PubMed ID: 2435052)
1. Correction to "Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas".
Thorac Cancer; 2023 Dec; 14(35):3499. PubMed ID: 37881131
[No Abstract] [Full Text] [Related]
2. Gene expression of mesothelioma in vinylidene chloride-exposed F344/N rats reveal immune dysfunction, tissue damage, and inflammation pathways.
Blackshear PE; Pandiri AR; Nagai H; Bhusari S; Hong HH; Ton TV; Clayton NP; Wyde M; Shockley KR; Peddada SD; Gerrish KE; Sills RC; Hoenerhoff MJ
Toxicol Pathol; 2015 Feb; 43(2):171-85. PubMed ID: 24958746
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous mesotheliomas in F344/N rats are characterized by dysregulation of cellular growth and immune function pathways.
Blackshear PE; Pandiri AR; Ton TV; Clayton NP; Shockley KR; Peddada SD; Gerrish KE; Sills RC; Hoenerhoff MJ
Toxicol Pathol; 2014 Jul; 42(5):863-76. PubMed ID: 23980201
[TBL] [Abstract][Full Text] [Related]
4. Pleural mesothelioma in a nine-month-old dog.
Vural SA; Ozyildiz Z; Ozsoy SY
Ir Vet J; 2007 Jan; 60(1):30-3. PubMed ID: 21851687
[TBL] [Abstract][Full Text] [Related]
5. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.
Linn SC; Honkoop AH; Hoekman K; van der Valk P; Pinedo HM; Giaccone G
Br J Cancer; 1996 Jul; 74(1):63-8. PubMed ID: 8679460
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
[TBL] [Abstract][Full Text] [Related]
7. Practical suggestions for successful immunoenzyme double-staining experiments.
van der Loos CM; Becker AE; van den Oord JJ
Histochem J; 1993 Jan; 25(1):1-13. PubMed ID: 7679380
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
Lung; 1995; 173(2):79-87. PubMed ID: 7536281
[TBL] [Abstract][Full Text] [Related]
9. Expression of developmentally regulated muscle proteins in rhabdomyosarcomas.
Wijnaendts LC; van der Linden JC; van Unnik AJ; Delemarre JF; Barbet JP; Butler-Browne GS; Meijer CJ
Am J Pathol; 1994 Oct; 145(4):895-901. PubMed ID: 7524332
[TBL] [Abstract][Full Text] [Related]
10. A new monoclonal antibody (3A5) that recognises a fixative resistant epitope on tissue macrophages and monocytes.
Jaspars EH; Bloemena E; Bonnet P; Scheper RJ; Kaiserling E; Meijer CJ
J Clin Pathol; 1994 Mar; 47(3):248-52. PubMed ID: 7512995
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.
Ruizeveld de Winter JA; Janssen PJ; Sleddens HM; Verleun-Mooijman MC; Trapman J; Brinkmann AO; Santerse AB; Schröder FH; van der Kwast TH
Am J Pathol; 1994 Apr; 144(4):735-46. PubMed ID: 7512791
[TBL] [Abstract][Full Text] [Related]
12. [Pleural mesothelioma--problems in diagnosis and clinical course in 25 patients].
Liewald F; Sunder-Plassmann L; Dienemann H; Mezger J
Langenbecks Arch Chir; 1989; 374(2):105-10. PubMed ID: 2704280
[TBL] [Abstract][Full Text] [Related]
13. Two colour DNA in situ hybridization for the detection of two viral genomes using non-radioactive probes.
Mullink H; Walboomers JM; Raap AK; Meyer CJ
Histochemistry; 1989; 91(3):195-8. PubMed ID: 2542189
[TBL] [Abstract][Full Text] [Related]
14. Sinonasal non-Hodgkin's lymphomas and Wegener's granulomatosis: a clinicopathological study.
Noorduyn LA; Torenbeek R; van der Valk P; Drosten PB; Snow GB; Balm AJ; Ossenkoppele GJ; Meyer CJ
Virchows Arch A Pathol Anat Histopathol; 1991; 418(3):235-40. PubMed ID: 1900969
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma.
Mullink H; Henzen-Logmans SC; Alons-van Kordelaar JJ; Tadema TM; Meijer CJ
Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 52(1):55-65. PubMed ID: 2435052
[TBL] [Abstract][Full Text] [Related]
16. The use of vimentin antibodies in the diagnosis of malignant mesothelioma.
Jasani B; Edwards RE; Thomas ND; Gibbs AR
Virchows Arch A Pathol Anat Histopathol; 1985; 406(4):441-8. PubMed ID: 3925619
[TBL] [Abstract][Full Text] [Related]
17. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
19. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
